Process development for an effective COVID-19 vaccine candidate harboring recombinant SARS-CoV-2 delta plus receptor binding domain produced by Pichia pastoris

[1]  Zhiyuan Li,et al.  Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis , 2022, Emerging microbes & infections.

[2]  N. Sadeghifard,et al.  Viral vector and nucleic acid vaccines against COVID-19: A narrative review , 2022, Frontiers in Microbiology.

[3]  D. Barouch.  Covid-19 Vaccines — Immunity, Variants, Boosters , 2022, The New England journal of medicine.

[4]  Xiaoming Yang,et al.  Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants , 2022, Vaccines.

[5]  S. Khoshnood,et al.  A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19 , 2022, Frontiers in Microbiology.

[6]  P. Hotez,et al.  Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern , 2022, Vaccine.

[7]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[8]  Vivek P. Chavda,et al.  Global impact of delta plus variant and vaccination , 2022, Expert review of vaccines.

[9]  Plos Medicine Editors.  Vaccine equity: A fundamental imperative in the fight against COVID-19 , 2022, PLoS medicine.

[10]  S. Kulshrestha,et al.  Correction to: Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe , 2022, Infection.

[11]  T. Peto,et al.  Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants , 2022, The New England journal of medicine.

[12]  Jordan J. Clark,et al.  Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.

[13]  S. Kulshrestha,et al.  Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe , 2021, Infection.

[14]  S. Elbashir,et al.  Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice , 2021, Vaccine.

[15]  I. Diamond,et al.  Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.

[16]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.

[17]  J. Montaner,et al.  Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults , 2021, medRxiv.

[18]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[19]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[20]  P. Korkusuz,et al.  Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection , 2021, Allergy.

[21]  P. Hotez,et al.  Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity , 2021, bioRxiv.

[22]  P. Hotez,et al.  SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice , 2021, Human vaccines & immunotherapeutics.

[23]  L. Bekker,et al.  From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward. , 2021, The New England journal of medicine.

[24]  B. Pulendran,et al.  Emerging concepts in the science of vaccine adjuvants , 2021, Nature reviews. Drug discovery.

[25]  Esteban Ortiz Prado,et al.  SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates , 2021, npj Vaccines.

[26]  Esteban Ortiz Prado,et al.  SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates , 2021, NPJ vaccines.

[27]  Cem Albayrak,et al.  Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro , 2021, bioRxiv.

[28]  P. Hotez,et al.  Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1 , 2020, Applied Microbiology and Biotechnology.

[29]  J. Pollet,et al.  Recombinant protein vaccines, a proven approach against coronavirus pandemics , 2020, Advanced Drug Delivery Reviews.

[30]  P. Hotez,et al.  Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate , 2020, Biochimica et Biophysica Acta (BBA) - General Subjects.

[31]  S. Perlman,et al.  COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice , 2020, Nature.

[32]  P. Hotez,et al.  SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice , 2020, bioRxiv.

[33]  Yong-tang Zheng,et al.  S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates , 2020, Nature Communications.

[34]  P. Hotez,et al.  Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement , 2020, Vaccine.

[35]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[36]  Matthew S. Miller,et al.  Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.

[37]  Lisa E. Gralinski,et al.  A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.

[38]  Yan Li,et al.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.

[39]  Yuquan Wei,et al.  A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.

[40]  P. Hotez,et al.  Developing a low-cost and accessible COVID-19 vaccine for global health , 2020, PLoS neglected tropical diseases.

[41]  A. Sette,et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.

[42]  T. Zhao,et al.  A Mouse Model of SARS-CoV-2 Infection and Pathogenesis , 2020, Cell Host & Microbe.

[43]  K. Ishii,et al.  Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant , 2020, Pharmaceutics.

[44]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[45]  H. Renz,et al.  Antigen , 2020, Definitions.

[46]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[47]  Chi‐Huey Wong,et al.  Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris. , 2019, Virology.

[48]  Derek T O'Hagan,et al.  Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want , 2018, npj Vaccines.

[49]  C. Fox,et al.  Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want , 2018, npj Vaccines.

[50]  Kevin S. Naceanceno,et al.  Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen , 2018, Vaccine.

[51]  Elissa M. Hudspeth,et al.  Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate , 2017, Journal of Pharmaceutical Sciences.

[52]  M. Ramakrishnan.  Determination of 50% endpoint titer using a simple formula. , 2016, World journal of virology.

[53]  Caifeng Zhao,et al.  Role of N-linked glycosylation in the secretion and enzymatic properties of Rhizopus chinensis lipase expressed in Pichia pastoris , 2015, Microbial Cell Factories.

[54]  Elissa M. Hudspeth,et al.  Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate , 2014, Human vaccines & immunotherapeutics.

[55]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[56]  P. Marik,et al.  Narrative Review , 2012, Journal of intensive care medicine.

[57]  U. Rinas,et al.  Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the Hepatitis B surface antigen , 2011, Microbial cell factories.

[58]  Leonard A. Smith,et al.  Cell bank characterization and fermentation optimization for production of recombinant heavy chain C-terminal fragment of botulinum neurotoxin serotype E (rBoNTE(H(c)): antigen E) by Pichia pastoris. , 2007, Journal of biotechnology.

[59]  David K. Meyerholz,et al.  Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.

[60]  F. Castellino,et al.  Glycosylation of Pichia pastoris ‐derived proteins , 1999, Biotechnology and applied biochemistry.

[61]  E. Raz,et al.  Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. , 1999, Cellular immunology.

[62]  G. Letchworth,et al.  High efficiency transformation by electroporation of Pichia pastoris pretreated with lithium acetate and dithiothreitol. , 2004, BioTechniques.